Mackenzie Financial Corp cut its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 93.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 48,594 shares of the company's stock after selling 681,934 shares during the quarter. Mackenzie Financial Corp's holdings in Qiagen were worth $1,928,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Qiagen in the 4th quarter worth approximately $202,000. Wells Fargo & Company MN lifted its holdings in shares of Qiagen by 31.8% in the 4th quarter. Wells Fargo & Company MN now owns 66,779 shares of the company's stock worth $2,974,000 after acquiring an additional 16,106 shares during the last quarter. GAMMA Investing LLC grew its position in Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares during the last quarter. LPL Financial LLC raised its position in Qiagen by 2.6% during the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after acquiring an additional 432 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Qiagen by 66.3% during the fourth quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company's stock worth $2,807,000 after buying an additional 25,134 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.
Qiagen Stock Up 1.3%
NYSE:QGEN traded up $0.62 on Thursday, reaching $48.11. The stock had a trading volume of 1,136,136 shares, compared to its average volume of 1,386,125. The company has a 50-day moving average of $47.89 and a 200 day moving average of $43.53. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. The stock has a market cap of $10.70 billion, a P/E ratio of 28.41, a price-to-earnings-growth ratio of 2.54 and a beta of 0.64. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88.
Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 earnings per share. On average, research analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current year.
Qiagen Announces Dividend
The company also recently announced a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. This represents a dividend yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. Qiagen's payout ratio is 14.79%.
Wall Street Analyst Weigh In
QGEN has been the topic of several research analyst reports. Bank of America raised their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Barclays assumed coverage on shares of Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. UBS Group lifted their target price on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday. Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Thursday. Finally, Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Eight research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Qiagen currently has a consensus rating of "Hold" and an average target price of $49.69.
Check Out Our Latest Report on Qiagen
Qiagen Profile
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Featured Articles
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
